DELIVERY OF ULTRAVIOLET-INACTIVATED S-35 HERPESVIRUS ACROSS AN OSMOTICALLY MODIFIED BLOOD-BRAIN-BARRIER

被引:35
作者
NEUWELT, EA
PAGEL, MA
DIX, RD
机构
[1] OREGON HLTH SCI UNIV, DEPT NEUROSURG, PORTLAND, OR 97201 USA
[2] OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA
[3] UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, DEPT OPHTHALMOL, MIAMI, FL 33152 USA
[4] UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33152 USA
[5] UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, DEPT NEUROL, MIAMI, FL 33152 USA
关键词
BLOOD-BRAIN BARRIER; HERPESVIRUS; REPLICATION-DEFECTIVE VECTORS;
D O I
10.3171/jns.1991.74.3.0475
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The present studies were undertaken to determine if viral particles can be delivered across the rat blood-brain barrier (BBB). Osmotic BBB modification with intracarotid mannitol (25%) was immediately followed by bolus intracarotid administration of 0.5 ml purified, ultraviolet-inactivated, herpes simplex virus type 1 endogenously labeled with S-35-labeled methionine (2.0 x 10(6) cpm, approximately 5 x 10(8) plaque-forming units/ml). After 60 minutes, intravascular virus was cleared by saline perfusion and the animals were sacrificed. A marked increase (fourfold, p less-than-or-equal-to 0.02) in radioactivity was observed in the ipsilateral brain hemisphere when compared to control animals without barrier modification. Administration of intravenous virus immediately after BBB modification displayed no difference in delivery when compared to intracarotid saline-infused controls (without BBB modification) suggesting the importance of a first-pass phenomenon. There were no significant differences in serum concentrations among intracarotid or intravenous groups. These preliminary studies suggest the possibility of delivering viral particles across the BBB with osmotic disruption, which may permit delivery of genetic material in replication-defective viral vectors in the feline model of G(M2)-gangliosidosis.
引用
收藏
页码:475 / 479
页数:5
相关论文
共 27 条
[1]   PROSPECTS FOR HUMAN-GENE THERAPY [J].
ANDERSON, WF .
SCIENCE, 1984, 226 (4673) :401-409
[2]  
Baker H J, 1982, Prog Clin Biol Res, V94, P203
[3]   MORPHOLOGICAL AND NEUROCHEMICAL INVESTIGATIONS OF 2-TYPES OF AMAUROTIC IDIOCY IN DOG - EVIDENCE OF A GM2-GANGLIOSIDOSIS [J].
BERNHEIMER, H ;
KARBE, E .
ACTA NEUROPATHOLOGICA, 1970, 16 (03) :243-+
[4]   CLINICAL NEUROGENETICS - SURVEY OF RELATIONSHIP OF MEDICAL GENETICS TO CLINICAL NEUROLOGY [J].
BIRD, TD ;
HALL, JG .
NEUROLOGY, 1977, 27 (11) :1057-1060
[5]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED GLUCOCEREBROSIDASE IN GAUCHERS-DISEASE [J].
BRADY, RO ;
PENTCHEV, PG ;
GAL, AE ;
HIBBERT, SR ;
DEKABAN, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (19) :989-993
[6]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED CERAMIDETRIHEXOSIDASE IN FABRYS-DISEASE [J].
BRADY, RO ;
TALLMAN, JF ;
JOHNSON, WG ;
GAL, AE ;
LEAHY, WR ;
QUIRK, JM ;
DEKABAN, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (01) :9-14
[7]  
BRADY RO, 1980, ENZYME THERAPY GENET, V2, P361
[8]   INFECTION OF CULTURED CENTRAL-NERVOUS-SYSTEM NEURONS WITH A DEFECTIVE HERPES-SIMPLEX VIRUS-1 VECTOR RESULTS IN STABLE EXPRESSION OF ESCHERICHIA-COLI BETA-GALACTOSIDASE [J].
GELLER, AI ;
FREESE, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (03) :1149-1153
[9]   A DEFECTIVE HSV-1 VECTOR EXPRESSES ESCHERICHIA-COLI BETA-GALACTOSIDASE IN CULTURED PERIPHERAL NEURONS [J].
GELLER, AI ;
BREAKEFIELD, XO .
SCIENCE, 1988, 241 (4873) :1667-1669
[10]   PARTIAL CORRECTION OF MURINE HEREDITARY GROWTH DISORDER BY GERM-LINE INCORPORATION OF A NEW GENE [J].
HAMMER, RE ;
PALMITER, RD ;
BRINSTER, RL .
NATURE, 1984, 311 (5981) :65-67